Petros Pharmaceuticals Inc (PTPI)
0.69
+0.03
(+4.99%)
USD |
NASDAQ |
May 02, 16:00
0.765
+0.08
(+10.87%)
After-Hours: 20:00
Petros Pharmaceuticals Cash from Financing (TTM): 11.54M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 11.54M |
| September 30, 2023 | 13.73M |
| June 30, 2023 | -1.268M |
| March 31, 2023 | -1.082M |
| December 31, 2022 | -1.624M |
| September 30, 2022 | 22.58M |
| June 30, 2022 | 21.26M |
| Date | Value |
|---|---|
| March 31, 2022 | 19.80M |
| December 31, 2021 | 18.57M |
| September 30, 2021 | 15.55M |
| June 30, 2021 | 19.74M |
| March 31, 2021 | 26.80M |
| December 31, 2020 | 30.30M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-1.624M
Minimum
Dec 2022
30.30M
Maximum
Dec 2020
15.07M
Average
18.57M
Median
Dec 2021
Cash from Financing (TTM) Benchmarks
| Avalo Therapeutics Inc | 25.04M |
| Spectral AI Inc | -- |
| Imunon Inc | -3.639M |
| Assembly Biosciences Inc | 13.82M |
| iBio Inc | 10.68M |